Ohio State Furthers Commitment To Bold Leadership in Cancer Research

February 01, 2013

COLUMBUS, Ohio – The Ohio State University Board of Trustees today (2/1) approved the appointment of four new chairs for cancer research at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC­­–James).

With these appointments, Ohio State now has 25 endowed chairs in cancer research and treatment.

“We are grateful to the University Board of Trustees and our generous donors for their unwavering support to furthering Ohio State’s commitment to bold leadership in finding new, more effective ways to prevent, detect, treat and cure cancer, a disease that has plagued our world for generations,” said Dr. Michael Caligiuri, director of Ohio State’s Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute.

“Specifically, these four endowed chairs help us recruit and retain world renowned leaders in lung cancer research, cancer prevention, cancer drug development and translational research that brings the latest discoveries to our cancer patients in the form of clinical trials,” said Caligiuri. “That brings some of the world’s greatest minds in cancer right here to Ohio State.”

By recruiting and retaining the best and brightest cancer researchers, Caligiuri explained that Ohio State is also bringing millions of dollars in cancer research grants to the institution. Currently, Ohio State ranks 15th among all cancer centers across the country in research funding from the National Cancer Institute.

“At a time when many institutions are scaling back their commitments to research and finding their philanthropic support waning, Ohio State is moving forward with great strides, both in philanthropic and in institutional support for cancer research and care,” Caligiuri said.

The new cancer chairs are:

  • Dr. David P. Carbone, Professor – Barbara J. Bonner Chair in Lung Cancer Research. Carbone leads a new thoracic oncology center at OSUCCC–James.
  • Dr. Steven K. Clinton, Professor – The John B. and Jane T. McCoy Chair in Cancer Research. Clinton leads the Molecular and Carcinogenesis and Chemoprevention Program at OSUCCC – James.
  • Dr. Michael R. Grever, Professor – The Bertha Bouroncle, M.D., and Andrew Pereny Chair of Medicine. Grever co-leads the Experimental Therapeutics Program at OSUCCC-James.
  • Dr. Guido Marcucci, Professor – The Charles Austin Doan Chair of Medicine. Marcucci is associate director for translational research at OSUCCC–James.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 228-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S. News & World Report.

# # #

Contact: Eileen Scahill, Wexner Medical Center Public Affairs and Media Relations, 614-293-3737, or Eileen.Scahill@osumc.edu

Contact Media Staff

Amanda Harper

Director of Media Relations

614-685-5420 (direct)

614-293-3737 (main)


Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.


If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

Drug Harnesses Immune System To Combat Most Common Form of Lung Cancer

Recently approved immunotherapy drugs are offering patients – and their oncologists – new hope for extending survival of people with advanced non-small cell lung cancer (NSCLC).

Investigational Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers

New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health. The experimental agent, known as AR-42 while in...

One Day to Help Create More Healthy — And Cancer-Free — Tomorrows

Through the generous support of Don and Angie Ward, all donations made to Ohio State's cancer program today (Nov. 24) through Giving Tuesday (Dec. 1), will be matched, 100 percent, up to $50,000.